SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 24, 2005
Commission File Number: 000-21376
Bio-Life Labs, Inc.
-------------------
(Exact name of registrant as specified in its charter)
Nevada 33-0714007
------ ----------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
16 Concord Rd., El Paso, TX 79906 79906
--------------------------------- -----
(Address of principal executive offices) (Zip Code)
(915) 843-2044
--------------
(Registrant's Telephone Number, Including Area Code)
ITEM 8.01: OTHER EVENTS
Bio-Life Labs, Inc., a Nevada corporation (the "Registrant") has entered into a
Settlement Agreement dated March 23, 2005 that settles and releases all claims
against the Company; its CEO, President and Chairman Nancy LeMay; and its
Executive Vice President and Director David Karam, M.D., Ph.D. by Plaintiff Zach
Thomas who was seeking to enforce an alleged oral agreement with Dr. Karam.
Plaintiff Thomas alleged that Dr. Karam agreed to issue Plaintiff Thomas 25 % of
his personal equity in Bio-Life Labs, Inc.
Under the terms of the Settlement, Dr. Karam agreed to issue 20% (5,921,932) of
his personally-owned shares of common stock to the Plaintiffs.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
March 27, 2005 Bio-Life Labs, Inc.
By: /s/ Nancy LeMay
--------------------------------
Nancy LeMay, President